Authors
Aristotle Bamias, Gerasimos Aravantinos, Ch Deliveliotis, D Bafaloukos, C Kalofonos, N Xiros, A Zervas, D Mitropoulos, E Samantas, D Pectasides, P Papakostas, D Gika, C Kourousis, A Koutras, C Papadimitriou, C Bamias, P Kosmidis, MA Dimopoulos
Publication date
2004/1/15
Journal
Journal of Clinical Oncology
Volume
22
Issue
2
Pages
220-228
Publisher
American Society of Clinical Oncology
Description
Purpose
The combination of methotrexate, vinblastine, doxorubicin, and cisplatin (MVAC) represents the standard regimen for inoperable or metastatic urothelial cancer, but its toxicity is significant. We previously reported a 52% response rate (RR) using a docetaxel and cisplatin (DC) combination. The toxicity of this regimen compared favorably with that reported for MVAC. We thus designed a randomized phase III trial to compare DC with MVAC.
Patients and Methods
Patients with inoperable or metastatic urothelial carcinoma; adequate bone marrow, renal, liver, and cardiac function; and Eastern Cooperative Oncology Group performance status ≤ 2 were randomly assigned to receive MVAC at standard doses or docetaxel 75 mg/m2 and cisplatin 75 mg/m2 every 3 weeks. All patients received prophylactic granulocyte colony-stimulating factor (G-CSF) support.
Results …
Total citations
Scholar articles
A Bamias, G Aravantinos, C Deliveliotis, D Bafaloukos… - Journal of Clinical Oncology, 2004